Expert Interviews

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

This episode, titled “Moving Beyond Long-Term Topical Corticosteroid Use in Inflammatory Dermatoses,” features panelists discussing the evolving role of topical corticosteroids in the management of chronic inflammatory skin diseases. Building on the consensus statement that topical corticosteroids should not be routinely prescribed for long-term use in chronic conditions, the expert faculty examine the distinction between acute flare management and long-term disease control.

In “Reducing Treatment Burden in Inflammatory Dermatoses,” our panel explores the practical challenges associated with managing chronic inflammatory skin diseases using multiple topical corticosteroids. Building on the consensus statement that the use of different corticosteroids for different body areas can create significant burden for patients, the expert faculty discuss how increasingly complex treatment regimens can negatively impact adherence, disease control, and the overall patient experience.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

The panel explores how to differentiate CSU from chronic inducible urticaria and acute urticaria, including the potential for overlap between subtypes.

In this episode titled "Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD address the clinical distinction between active and stable vitiligo, as well as the significant psychological impact of the disease.

The panel examines how to distinguish CSU from other urticaria subtypes, how to approach angioedema, and how limited—or expansive—the diagnostic workup should be.

In this episode titled "Vitiligo Pathogenesis: How the JAK-STAT Pathway Drives Melanocyte Destruction," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD explore the immunological underpinnings of vitiligo and how this understanding has revolutionized treatment thinking.

Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.

LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.

Explore cutaneous SCC care from topical therapies and Mohs to adjuvant radiation and PD-1 immunotherapy, guided by shared decisions and profiling.

Learn how cutaneous SCC care shifts from topical therapy to Mohs, radiation, and PD-1 immunotherapy, guided by shared decisions and profiling.

Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

Kord Honda, MD, provides his first-line and adjunct treatment strategies for acne in recognition of Acne Awareness Month.

Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.

Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.

The panel turns to taking a thorough patient history, performing a complete physical exam, and ordering appropriate laboratory workup when evaluating a patient with vitiligo.

In this episode, “Understanding Corticosteroid Risks in Inflammatory Dermatoses,” the expert faculty explore the key findings from a recent consensus paper evaluating the risks associated with topical and systemic corticosteroid therapy and the role of advanced targeted topical treatments in inflammatory skin diseases. The panel reviews the methodology behind the expert consensus process, including the comprehensive literature review and evidence-based approach used to develop recommendations for clinical practice.

The panel reviews the first patient case—a 38-year-old woman with recurrent hives and intermittent swelling—highlighting the key clinical criteria that clinch a CSU diagnosis.

A national survey examines the pressures facing independent dermatologists and strategies to strengthen practice performance.

Welcome back to another Dermatology Times Between the Lines series. In this episode titled, “Rethinking Long-Term Management of Inflammatory Dermatoses,” the expert faculty discuss the chronic, relapsing nature of inflammatory skin diseases and how advances in our understanding of underlying inflammation have influenced treatment goals. The panel explores commonly encountered inflammatory dermatoses, including atopic dermatitis, psoriasis, and seborrheic dermatitis, and examines how durable disease control has become an increasingly important objective in clinical practice.

The panel reframe vitiligo as a chronic autoimmune disease affecting 1–2% of the global population, emphasizing its clinical presentations, associated comorbidities, and significant psychosocial impact on patients across all skin types.

The panel reflects on dermatology's evolving role in CSU, from limited options and reluctance to a new era of empowered, effective disease management.

Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.

Learn why gene expression profiling in cutaneous SCC can’t yet guide imaging or radiation decisions—and what evidence gaps still limit its use.

Gene expression profiling flags hidden high-risk cutaneous